Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nathaniel Katz

Showing results (11-20 of 67) with videos related to

Pageof 7
Sort By:
Contemporary Clinical Trials|July 8, 2021
What can be done to control the placebo response in clinical trials? A narrative reviewKathryn Evans, Luana Colloca, Marta Pecina, et al.
Postgraduate Medicine|August 3, 2010
Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis painNathaniel Katz, Martin Hale, David Morris, et al.
The Journal of Pain|March 20, 2012
Dose equivalence of immediate-release hydromorphone and once-daily osmotic-controlled extended-release hydromorphone: a randomized, double-blind trial incorporating a measure of assay sensitivityRicardo A Cruciani, Nathaniel Katz, Russell K Portenoy
The Journal of Pain|December 1, 2009
ALO-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safetyNathaniel Katz, Stephen Sun, Franklin Johnson, et al.
The Journal of Pain|November 25, 2014
A review of the use of the number needed to treat to evaluate the efficacy of analgesicsNathaniel Katz, Florence C Paillard, Richard Van Inwegen
Cephalalgia : an International Journal of Headache|September 22, 2020
The relation between the placebo response, observed treatment effect, and failure to meet primary endpoint: A systematic review of clinical trials of preventative pharmacological migraine treatmentsKathryn Evans, Heather Romero, Egilius Lh Spierings, et al.
Current Medical Research and Opinion|May 14, 2004
Onset of pain relief with rofecoxib in chronic low back pain: results of two four-week, randomized, placebo-controlled trialsNathaniel Katz, Diana B Rodgers, David Krupa, et al.
Pain|July 27, 2017
Safety and efficacy of neublastin in painful lumbosacral radiculopathy: a randomized, double-blinded, placebo-controlled phase 2 trial using Bayesian adaptive design (the SPRINT trial)Miroslav Backonja, Leslie Williams, Xiaopeng Miao, et al.
Applied Health Economics and Health Policy|June 30, 2009
Development of a budget-impact model to quantify potential cost savings from prescription opioids designed to deter abuse or ease of extractionAlan G White, Howard G Birnbaum, Dov B Rothman, et al.
The Clinical Journal of Pain|October 21, 2020
A 3-way Cross-over Study of Pregabalin, Placebo, and the Histamine 3 Receptor Inverse Agonist AZD5213 in Combination With Pregabalin in Patients With Painful Diabetic Neuropathy and Good Pain-reporting AbilityRobert C Alexander, Karen Raudibaugh, Egilius L H Spierings, et al.
Pageof 7

Showing results (11-20 of 67) with videos related to

Sort By:
Pageof 7
Contemporary Clinical Trials|July 8, 2021
What can be done to control the placebo response in clinical trials? A narrative reviewKathryn Evans, Luana Colloca, Marta Pecina, et al.
Postgraduate Medicine|August 3, 2010
Morphine sulfate and naltrexone hydrochloride extended release capsules in patients with chronic osteoarthritis painNathaniel Katz, Martin Hale, David Morris, et al.
The Journal of Pain|March 20, 2012
Dose equivalence of immediate-release hydromorphone and once-daily osmotic-controlled extended-release hydromorphone: a randomized, double-blind trial incorporating a measure of assay sensitivityRicardo A Cruciani, Nathaniel Katz, Russell K Portenoy
The Journal of Pain|December 1, 2009
ALO-01 (morphine sulfate and naltrexone hydrochloride) extended-release capsules in the treatment of chronic pain of osteoarthritis of the hip or knee: pharmacokinetics, efficacy, and safetyNathaniel Katz, Stephen Sun, Franklin Johnson, et al.
The Journal of Pain|November 25, 2014
A review of the use of the number needed to treat to evaluate the efficacy of analgesicsNathaniel Katz, Florence C Paillard, Richard Van Inwegen
Cephalalgia : an International Journal of Headache|September 22, 2020
The relation between the placebo response, observed treatment effect, and failure to meet primary endpoint: A systematic review of clinical trials of preventative pharmacological migraine treatmentsKathryn Evans, Heather Romero, Egilius Lh Spierings, et al.
Current Medical Research and Opinion|May 14, 2004
Onset of pain relief with rofecoxib in chronic low back pain: results of two four-week, randomized, placebo-controlled trialsNathaniel Katz, Diana B Rodgers, David Krupa, et al.
Pain|July 27, 2017
Safety and efficacy of neublastin in painful lumbosacral radiculopathy: a randomized, double-blinded, placebo-controlled phase 2 trial using Bayesian adaptive design (the SPRINT trial)Miroslav Backonja, Leslie Williams, Xiaopeng Miao, et al.
Applied Health Economics and Health Policy|June 30, 2009
Development of a budget-impact model to quantify potential cost savings from prescription opioids designed to deter abuse or ease of extractionAlan G White, Howard G Birnbaum, Dov B Rothman, et al.
The Clinical Journal of Pain|October 21, 2020
A 3-way Cross-over Study of Pregabalin, Placebo, and the Histamine 3 Receptor Inverse Agonist AZD5213 in Combination With Pregabalin in Patients With Painful Diabetic Neuropathy and Good Pain-reporting AbilityRobert C Alexander, Karen Raudibaugh, Egilius L H Spierings, et al.
Pageof 7